KRAS inhibitor therapy for pancreatic cancer

Phase 3 clinical trial results for Revolution Medicines’ new oral agent daraxonrasib recently rocked the 2026 annual meeting of the American Society of Clinical Oncology (ASCO) with news that it had almost doubled life expectancy in the metastatic patients who took it compared to similar patients who had chemotherapy.

Fred Hutch Cancer Center clinicians, researchers and patients are also excited that science has finally figured out a way to drug the heretofore undruggable KRAS gene that’s mutated in over 90% of pancreatic cancers and also drives other aggressive cancers.

“It’s fantastic, obviously,” said Dr. Andrew Coveler, associate professor (Hematology and Oncology) and director of Fred Hutch’s Pancreatic Cancer Specialty Clinic. “It’s a paradigm-shifting treatment. It’s going to probably change treatment from chemotherapy to agents that target the mechanism that causes pancreas cancer. It really brings a whole new world of targeting to this disease and to other cancers, as well.”